Editas Medicine (EDIT) Expected to Announce Quarterly Earnings on Monday

Editas Medicine (NASDAQ:EDIT - Get Free Report) is anticipated to release its Q1 2025 earnings data after the market closes on Monday, May 12th. Analysts expect Editas Medicine to post earnings of ($0.52) per share and revenue of $0.79 million for the quarter.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.16). The company had revenue of $30.60 million for the quarter, compared to the consensus estimate of $37.17 million. Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. During the same period last year, the company earned ($0.23) EPS. On average, analysts expect Editas Medicine to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Editas Medicine Stock Up 4.3 %

NASDAQ:EDIT traded up $0.06 on Friday, hitting $1.45. The stock had a trading volume of 2,653,731 shares, compared to its average volume of 2,569,489. Editas Medicine has a 52 week low of $0.91 and a 52 week high of $6.69. The business's fifty day moving average is $1.37 and its 200 day moving average is $1.72. The company has a market cap of $121.38 million, a PE ratio of -0.57 and a beta of 2.15.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on EDIT shares. HC Wainwright assumed coverage on shares of Editas Medicine in a research report on Monday, April 28th. They issued a "buy" rating and a $3.00 price target for the company. Cantor Fitzgerald upgraded shares of Editas Medicine from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 29th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Editas Medicine presently has an average rating of "Hold" and a consensus target price of $6.54.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.